2023
Comparison of incident breast cancer cases in the largest national US tumor registries.
Plichta J, Thomas S, Record S, Hyslop T, Hwang E, Greenup R. Comparison of incident breast cancer cases in the largest national US tumor registries. Journal Of Clinical Oncology 2023, 41: 6512-6512. DOI: 10.1200/jco.2023.41.16_suppl.6512.Peer-Reviewed Original ResearchIncident breast cancer casesNumber of patientsRace/ethnicityBreast cancer casesTumor RegistryCase ascertainmentBreast cancerCancer casesPatient countsNon-Hispanic American Indian/Alaska NativesNational tumor registryYear of diagnosisMale breast cancerPopulation cancer registryBreast cancer patientsPacific Islander patientsAmerican Indians/Alaska NativesNon-Hispanic blacksNon-Hispanic whitesChi-square testPublic-use databaseFemale patientsHispanic patientsTreatment patternsCancer Registry
2022
Treatment patterns and medical costs of metastatic breast cancer care in the United States.
Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factor
2017
A population-based analysis of treatment and outcomes in 2,500 metaplastic breast cancer patients.
Ong C, Thomas S, Campbell B, Greenup R, Plichta J, Rosenberger L, Force J, Hyslop T, Hwang E, Fayanju O. A population-based analysis of treatment and outcomes in 2,500 metaplastic breast cancer patients. Journal Of Clinical Oncology 2017, 35: 532-532. DOI: 10.1200/jco.2017.35.15_suppl.532.Peer-Reviewed Original ResearchMetaplastic breast cancerMBC patientsOverall survivalWorse OSHigher clinical T stageMetaplastic breast cancer patientsCox proportional hazards modelNational Cancer DatabaseClinical T stageBreast cancer patientsPopulation-based analysisProportional hazards modelAxillary dissectionTN patientsReceptor statusTN subtypeAggressive variantHigher proportionLuminal subtypeT stageTreatment patternsEntire cohortKaplan-MeierCancer patientsSubgroup analysisImpact of insurance status on treatment for stage 0-IV breast cancer.
Greenup R, Thomas S, Fayanju O, Hyslop T, Hwang E. Impact of insurance status on treatment for stage 0-IV breast cancer. Journal Of Clinical Oncology 2017, 35: 6532-6532. DOI: 10.1200/jco.2017.35.15_suppl.6532.Peer-Reviewed Original ResearchRisk of deathInsurance statusBreast cancerStage 0Private insuranceMultivariate Cox proportional hazards modelStage 1 breast cancerUninsured breast cancer patientsNational Cancer Data BaseCox proportional hazards modelUnilateral stage 0Receipt of chemotherapyReceipt of surgeryStage 4 diseaseReceipt of treatmentBreast cancer patientsProportional hazards modelBinary logistic regressionNeoadjuvant chemotherapyOncologic outcomesOverall survivalBilateral mastectomyMedian ageUninsured womenTreatment patterns
2015
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ
Worni M, Akushevich I, Greenup R, Sarma D, Ryser M, Myers E, Hwang E. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ. Journal Of The National Cancer Institute 2015, 107: djv263. PMID: 26424776, PMCID: PMC4707192, DOI: 10.1093/jnci/djv263.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioProportional Hazards ModelsRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneSEER ProgramSentinel Lymph Node BiopsySurvival AnalysisTreatment OutcomeUnited StatesConceptsOverall survivalTreatment patternsPre-invasive breast cancerSentinel lymph node biopsyCox proportional hazards regressionLocoregional treatment optionsNational treatment trendsEnd Results registryLymph node biopsyBreast cancer outcomesLong-term outcomesProportional hazards regressionPatient selection biasCochran-Armitage trend testInverse probability weightsDCIS patientsNode biopsyBilateral mastectomyDuctal carcinomaHazards regressionCancer outcomesTreatment optionsBreast cancerTreatment trendsLumpectomy